source
- Scholar Rock receives FDA approval for apitegromab (Isembyld) to treat spinal muscular atrophyScholar Rock announced FDA approval for its injectable drug apitegromab, marketed as Isembyld, for treating spinal muscular atrophy, a rare muscle-wasting condition. The approval follows earlier s…
- GSK presents promising late-stage lung cancer data from two investigational drugsGSK highlighted late-stage results for two of its lung cancer candidates, reporting encouraging efficacy signals that could advance the programs toward regulatory review. The company shared the da…